CO76 Does Next Generation Sequencing (NGS) Improve Outcome in Non-Small Cell Lung Cancer (NSCLC)? A Real-World Data (RWD) Example

The objective of this analysis was to evaluate the impact of sequencing versus point mutation testing on outcomes in non-small cell lung cancer (NSCLC) using real-world data (RWD). Over time, there has been a shift in recommendations from single-gene or small-panel testing to broader genomic profiling with next-generation sequencing (NGS). In 2018, The Centers for Medicare and Medicaid Services (CMS) established the first national coverage for NGS for NSCLC. Since then, both CMS and compendial recommendations have continued to evolve, with increasing emphasis on NGS.
Source: Value in Health - Category: International Medicine & Public Health Authors: Source Type: research